The blog FiercePharma reports that the diabetes drug Victoza has performed well in a clinical study – performing better than competitors Januvia and Byetta in keeping patients’ blood sugar below a target of 7 percent.
Novo Nordisk, Victoza’s manufacturer, is working to secure more of an edge in what the blog entry describes as “the fast-growing diabetes market.” But it will likely face challenges in the form of a marketing blitz ...
continue reading...
Poxel SA, a France-based company spun off from the pharmaceutical division of Merck, has raised $17.1 million in venture backing to fund a clinical trial for an experimental Type 2 diabetes drug, Bloomberg reports.
According to Bloomberg, the compound imeglimin is part of a new class of oral anti-diabetics called glimins, and has shown promising results in previous trials.
A safer alternative to existing medications could be a potentially lucrative market for ...
continue reading...A report on the blog FiercePharma says that a more stringent warning label for the diabetes drug Byetta spooked some investors when the U.S. Food and Drug Administration issued it in 2008.
At the time, Byetta manufacturers Eli Lilly and Amylin Pharmaceuticals had been in the process of developing a version of the drug that had to be administered only once a week, as opposed to the twice-daily version then on ...
continue reading...A story by ABC News reports on the U.S. Food and Drug Administration’s changes to prescribing information for the diabetes drug Byetta, in response to reports about kidney problems.
According to the story, the FDA received 78 reports of kidney function problems from patients taking Byetta between April 2005 and October 2008, most of which occurred in patients with pre-existing kidney disease or one or more risk factors for developing kidney problems.
Studies have also linked Byetta, as well as the diabetes ...
continue reading...A new study says an increasing number of Americans are losing their eyesight, which may be a result of diabetes.
CBS News cites research concluding that from 1999 through 2002, about 1.4 percent of Americans had visual impairment. That percentage rose to 1.7 percent between 2005 and 2008, representing a 21 percent rise in rates. For non-Hispanic white Americans between 20 and 39 years old, that increase amounted to 40 percent.
Further ...
continue reading...The European Commission has approved a diabetes medicine that U.S. regulators have rejected, Reuters reports.
The medication, by Bristol-Myers Squibb Co and AstraZeneca Plc, is called Forxiga. It’s part of a new class of diabetes drugs that work independently of insulin to control blood sugar.
Its manufacturers are touting Forxiga’s capacity for lowering blood pressure and inducing weight loss. But when regulators with the U.S. Food and Drug Administration rejected it in ...
continue reading...
